BPMC - ブル―プリント・メディシンズ （Blueprint Medicines Corporation）BPMCのニュース
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021 2021/03/10 21:30:00 PR Newswire
CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the company's precision oncology and hematology portfolio at the American Association for…
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis 2021/03/03 13:00:00 PR Newswire
CAMBRIDGE, Mass., March 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company's Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of…
Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines By Investing.com 2021/02/19 09:13:16 Investing.com
Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results 2021/02/17 12:00:00 PR Newswire
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. "Last year was transformational for Blueprint Medicines, with four…
Blueprint Medicines Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis 2021/02/16 20:05:00 Stock Market Daily
Blueprint Medicines announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021 2021/03/10 21:30:00 PR Newswire
CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the company's precision oncology and hematology portfolio at the American Association for…
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis 2021/03/03 13:00:00 PR Newswire
CAMBRIDGE, Mass., March 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company's Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of…
Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines By Investing.com 2021/02/19 09:13:16 Investing.com
Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results 2021/02/17 12:00:00 PR Newswire
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. "Last year was transformational for Blueprint Medicines, with four…